Get started
Author

Bob Valamehr

Observed name: Bahram Valamehr
Observed institution: Fate Therapeutics (United States)
ORCID: 0000-0002-5917-3585
Observed ORCID: 0000-0002-5917-3585
OpenAlex ID: A5059754344
In Vivo Persistence and Function of Adaptive NK Cell Infusions (FATE-NK100) from CMV Seropositive Haploidentical Related Donors
2019 · Sarah Cooley, Melissa Geller, et al. · Transplantation and Cellular Therapy · 7
755 Results of a phase I trial of FT500, a first-in-class, off-the-shelf, iPSC–derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors
2022 · Sandip Patel, Manish Patel, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
204 Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity
2022 · John Goulding, Bryan Hancock, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
726 Phase I results of FT516, an off-the-shelf, iPSC-derived NK cell therapy expressing a high-affinity, non-cleavable CD16 (hnCD16) combined with avelumab in patients with advanced solid tumors
2022 · Martin Gutierrez, Manish Patel, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
120 Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors
2021 · Martin Hosking, Soheila Shirinbak, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors
2022 · Martin Gutierrez, Melissa Johnson, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
155 iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma
2020 · Jeffrey Miller, Frank Cichocki, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Induced pluripotent stem cell-derived natural killer cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3–targeted tri-specific killer engager
2026 · Jian-Fang Ning, Zachary B Davis, et al. · Neuro-Oncology · 1
304 Off-the-shelf iPSC-derived CAR-T cells containing seven functional edits overcome antigen heterogeneity, improve trafficking, and withstand immunosuppression associated with failed tumor treatment
2022 · Martin Hosking, Soheila Shirinbak, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
P-055 Conserved and Unique Pathways of Natural Killer Cell Resistance in Multiple Myeloma Cell Lines
2024 · Aimee Merino, Amit Mitra, et al. · Clinical Lymphoma Myeloma & Leukemia
341 Novel immune reconstitution model highlights the importance of stealth strategies that potentiate effector cell function and promote functional persistence of next-generation adoptive cell therapies
2022 · Ken Hayama, Alan Williams, et al. · Journal for ImmunoTherapy of Cancer
PDF
279 Preclinical in vivo model development: Highlighting success and discussing xenograft advancements, a step closer to predicting patient outcomes
2022 · Thomas Dailey, Angela Gentile, et al. · Journal for ImmunoTherapy of Cancer
PDF
259 iPSC-derived NK cells engineered with a novel TGFβ signal redirector receptor exhibit enhanced performance against solid tumors
2022 · Eigen Peralta, Dan Lu, et al. · Journal for ImmunoTherapy of Cancer
PDF
276 Engineering of synthetic chemokine receptors into iPSC-derived CAR-T cells to increase homing and enhance trafficking into solid tumors
2022 · Soheila Shirinbak, Joy Grant, et al. · Journal for ImmunoTherapy of Cancer
PDF
300 Tri-modal CAR+TCR+hnCD16+ iPSC-derived T cells co-targeting surface and intracellular/neoantigens demonstrate additive effect on overcoming tumor heterogeneity and cancer escape
2022 · Bi-Huei Yang, Soheila Shirinbak, et al. · Journal for ImmunoTherapy of Cancer
PDF
138 Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors
2021 · Eigen Peralta, Emily Carron, et al. · Journal for ImmunoTherapy of Cancer
PDF
169 Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo
2021 · Frank Cichocki, Jianfang Ning, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 609: Overcoming host histocompatibility barrier to create a renewable source of off-the-shelf effector lymphocytes for adoptive immunotherapy
2017 · Raedun L. Clarke, Matthieu Bauer, et al. · Cancer Research
Works count: 18
Citation count: 26
H-index: 3
I10-index:
Year
Topic
Type